| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
10,850 |
10,612 |
$1.41M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
4,598 |
4,371 |
$1.25M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
1,052 |
969 |
$120K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
3,322 |
3,243 |
$54K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
4,819 |
2,336 |
$53K |
| 80053 |
Comprehensive metabolic panel |
3,599 |
3,197 |
$22K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
140 |
138 |
$21K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
5,038 |
4,254 |
$16K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
94 |
92 |
$13K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
866 |
843 |
$7K |
| 81001 |
|
2,686 |
2,497 |
$5K |
| 71045 |
Radiologic examination, chest; single view |
986 |
915 |
$5K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
1,114 |
1,005 |
$5K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
58 |
53 |
$3K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
661 |
606 |
$3K |
| 87807 |
|
258 |
254 |
$2K |
| 70450 |
Computed tomography, head or brain; without contrast material |
108 |
103 |
$2K |
| 87070 |
|
463 |
452 |
$2K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
60 |
60 |
$2K |
| 84484 |
|
808 |
658 |
$1K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
582 |
449 |
$746.64 |
| 96361 |
Intravenous infusion, hydration; each additional hour |
76 |
52 |
$652.53 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
60 |
60 |
$435.07 |
| 81025 |
|
64 |
58 |
$381.40 |
| 83690 |
|
199 |
174 |
$363.11 |
| 96375 |
Therapeutic injection; each additional sequential IV push |
193 |
167 |
$341.36 |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
14 |
12 |
$310.59 |
| 82803 |
|
94 |
90 |
$174.11 |
| 85610 |
|
306 |
239 |
$136.44 |
| 86901 |
|
77 |
69 |
$97.63 |
| 83605 |
|
110 |
97 |
$96.71 |
| 86900 |
|
77 |
69 |
$95.12 |
| 86850 |
|
12 |
12 |
$85.66 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
151 |
134 |
$83.97 |
| 83735 |
|
80 |
66 |
$78.26 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
313 |
278 |
$37.29 |
| 83880 |
|
14 |
12 |
$32.98 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
98 |
94 |
$21.56 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
13 |
13 |
$11.73 |
| 85730 |
|
20 |
14 |
$5.05 |
| 82330 |
|
17 |
17 |
$1.53 |
| J1644 |
Injection, heparin sodium, per 1000 units |
18 |
12 |
$0.00 |
| A9270 |
Non-covered item or service |
32 |
26 |
$0.00 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
16 |
15 |
$0.00 |
| J2704 |
Injection, propofol, 10 mg |
12 |
12 |
$0.00 |